Journal article

Diabetic kidney disease

Merlin C Thomas, Michael Brownlee, Katalin Susztak, Kumar Sharma, Karin AM Jandeleit-Dahm, Sophia Zoungas, Peter Rossing, Per-Henrik Groop, Mark E Cooper



The kidney is arguably the most important target of microvascular damage in diabetes. A substantial proportion of individuals with diabetes will develop kidney disease owing to their disease and/or other co-morbidity, including hypertension and ageing-related nephron loss. The presence and severity of chronic kidney disease (CKD) identify individuals who are at increased risk of adverse health outcomes and premature mortality. Consequently, preventing and managing CKD in patients with diabetes is now a key aim of their overall management. Intensive management of patients with diabetes includes controlling blood glucose levels and blood pressure as well as blockade of the renin-angiotensin-al..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

M.C.T. has received honoraria for educational meetings conducted on behalf of AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharpe & Dohme, Servier, Novartis, Takeda, Abbott, Allergan and AstraZeneca. M.B. declares no competing interests. K. Susztak has received research support from Boehringer Ingelheim and Biogen Idec for projects not related to this publication, and is on the advisory board of AbbVie. She has received research support from the US National Institutes of Health (NIH), the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA). K. Sharma has received research support from AbbVie, Boehringer Ingelheim and Stealth Peptides for projects not related to this publication, and is on the scientific advisory board of Merck and Astellas. He is founder of Clinical Metabolomics, and has received research support from the NIH, the JDRF and the ADA. K.A.M.J-.D. has received research grants from Genkyotex and Boehringer Ingelheim. S.Z. has served on the advisory board for Amgen, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Sanofi and Takeda Pharmaceuticals. S.Z. has received consultancy fees and honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Merck Sharp & Dohme and Servier Laboratories. She has received grants from the National Health and Medical Research Council and the Heart Foundation of Australia, and has undertaken institutional contract work for Bristol-Myers Squibb and the Commonwealth Department of Health. P.R. has received consultancy and/or speaking fees (to his institution) from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sanofi Aventis, Astellas, AbbVie and Merck Sharp & Dohme. He has received research grants from AbbVie, Novo Nordisk and Astra Zeneca. P.R. has shares in Novo Nordisk. P-.H.G. has received lecture honoraria from Boehringer Ingelheim, AstraZeneca, Genzyme, Novartis, Novo Nordisk, Merck Sharp & Dohme, Eli Lilly and Company and Medscape. M.E.C. has received honoraria and consulting fees from AbbVie, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharpe and Dohme, Servier, Takeda, Novo Nordisk and AstraZeneca, as well as research grants from Novo Nordisk and AbbVie.